NEOGEN CORP (NEOG) Stock Fundamental Analysis
USA - NASDAQ:NEOG - US6404911066 - Common Stock
6.37 USD
-0.1 (-1.55%)
6.25 USD
-0.12 (-1.88%)
NEOG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. NEOG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEOG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year NEOG was profitable.
In the past year NEOG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
NEOG had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
NEOG has a Return On Assets of -30.88%. This is comparable to the rest of the industry: NEOG outperforms 42.86% of its industry peers.
The Return On Equity of NEOG (-49.23%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NEOG has a Gross Margin (46.39%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEOG has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for NEOG has been increased compared to 5 years ago.
NEOG has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.83, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.83, NEOG is in line with its industry, outperforming 50.79% of the companies in the same industry.
A Debt/Equity ratio of 0.37 indicates that NEOG is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.37, NEOG perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.83 |
ROIC/WACCN/A
WACC7.67%
2.3 Liquidity
A Current Ratio of 3.58 indicates that NEOG has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.58, NEOG is doing good in the industry, outperforming 66.67% of the companies in the same industry.
A Quick Ratio of 2.26 indicates that NEOG has no problem at all paying its short term obligations.
With a Quick ratio value of 2.26, NEOG perfoms like the industry average, outperforming 57.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
NEOG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.20% yearly.
The Revenue has decreased by -2.77% in the past year.
The Revenue has been growing by 16.43% on average over the past years. This is quite good.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
3.2 Future
Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
The Revenue is expected to grow by 0.76% on average over the next years.
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NEOG is valuated rather expensively with a Price/Earnings ratio of 21.23.
Compared to the rest of the industry, the Price/Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 79.37% of the companies listed in the same industry.
NEOG is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.91, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 18.37, NEOG is valued on the expensive side.
82.54% of the companies in the same industry are more expensive than NEOG, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.57, NEOG is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.23 | ||
| Fwd PE | 18.37 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NEOG is valued a bit cheaper than the industry average as 74.60% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.64 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.51%
EPS Next 3Y6.43%
5. Dividend
5.1 Amount
NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.37
-0.1 (-1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.45%
Inst Owner Change3.61%
Ins Owners0.42%
Ins Owner Change84.87%
Market Cap1.38B
Revenue(TTM)886.89M
Net Income(TTM)-1.04B
Analysts76.36
Price Target7.78 (22.14%)
Short Float %10.66%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)15.53%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)2
Avg EPS beat(8)-1.35%
EPS beat(12)4
Avg EPS beat(12)52.58%
EPS beat(16)5
Avg EPS beat(16)29.73%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)17.31%
PT rev (3m)17.31%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-13.15%
EPS NY rev (1m)-2.04%
EPS NY rev (3m)-33.33%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)-2.74%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.23 | ||
| Fwd PE | 18.37 | ||
| P/S | 1.56 | ||
| P/FCF | N/A | ||
| P/OCF | 15.91 | ||
| P/B | 0.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 20.64 |
EPS(TTM)0.3
EY4.71%
EPS(NY)0.35
Fwd EY5.44%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.29%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.03 | ||
| Cap/Depr | 75.94% | ||
| Cap/Sales | 10.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 88.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 0.83 |
F-Score3
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.71%
EBIT Next 5Y20.44%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
Can you provide the valuation status for NEOGEN CORP?
ChartMill assigns a valuation rating of 3 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.
What is the earnings growth outlook for NEOGEN CORP?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -25.82% in the next year.